MedTrace Logo

A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer

NCT03940001 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-09-09

No results posted yet for this study

Summary

The purpose of this study is to test the the efficacy and safety of sintilimab in combination with chemoradiation before surgery for esophageal cancer.

Conditions

Interventions

BIOLOGICAL

Sintilimab

Other Name: (IBI308)

DRUG

carboplatin/paclitaxel

carboplatin AUC 2/paclitaxel 50 mg/m2 weekly

RADIATION

Radiation

IMRT or VMAT

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • chen ming, MD · Zhejiang Cancer Hospital

  • chen qixun, MD · Zhejiang Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2021-05-01
Completion
2022-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03940001 on ClinicalTrials.gov